本次研讨会由清华大学祁海教授、斯坦福大学Mark Davis教授、英国弗朗西斯·克里克研究所Carola Vinuesa教授和墨尔本大学Laura ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

3月10日，辉瑞公司（Pfizer）宣布其双特异性抗体新药 埃纳妥单抗（ elranatamab）已获国家药品监督管理局 （NMPA）附条件批准上市， 适用于既往接受过至少三线治疗（包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体） ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ann ...

The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...

The partnership leverages the sensitive, specific and safe (3S) TCR characterisation and generation capabilities of Medigene and EpimAb’s cluster of differentiation 3 (CD3) antibody and TCR-Fab in ...

Cedric Bloch will be back in TCR UK this season following his debut in the championship last year and will race full season in an Audi RS 3 LMS TCR DSG in the Gen 1 Cup. “I enjoyed the 2024 season and ...

TCR generation and characterization capabilities and EpimAb’s proprietary CD3 antibody and T-FIT (TCR-Fab in tandem) platform. The resultant bispecific therapeutics are expected to provide ...

The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...